Oculus Innovative Sciences Announces Completion of Patient Follow-Up in Scar Management Study

Oculus Innovative Sciences Announces Completion of Patient Follow-Up in Scar
Management Study

PETALUMA, Calif., March 14, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS), a commercial healthcare company that designs,
produces and markets innovative, safe and effective drugs, devices and
nutritional products, including Microcyn® Technology solutions which are used
in multiple markets including dermatology, post-surgical, wound care, and
animal healthcare, today announced completion of the 112-day follow-up period
in the company's clinical trial for the management of hypertrophic or keloid
scars. The 40-patient comparative, double-blinded and randomized clinical
study was based on an FDA-approved protocol. Patients were enrolled at four
different U.S. clinical sites, includingAlbuquerque, NM,High Point,
NC,Austin, TXandCollege Station, TX.

The company is encouraged by the initial clinical trial results from the
management of scars trial and expects to complete data analysis and submit the
510k application to the FDA for review within the next 60 to 90 days. In
accordance with FDA regulations, the company expects to release the data
immediately after completion of FDA's review. TheFDA's standard review time
from submission to clearance is ninety days, although industry averages
suggest this process can take up to six months.

The trial's primary endpoint was to compare a uniquely formulated Microcyn
Technology-based hydrogel versus a dimethicone comparatorusing the Vancouver
Scar Scale that measured vascularity, height/thickness, pliability and
pigmentation of scars. There were no direct product-related serious adverse
events in either arm reported during the study. Secondary endpoints included
themeasurements ofpain and itch and other reported adverse events and
treatment satisfaction as reported by patients through a questionnaire.

"According to a LifeSci Advisors 2012 report, there are currently no
FDA-approved pharmaceuticalsindicated to reduce scar severity and several
available procedure-based and over-the-counter treatments are either invasive,
costly or have been reported with limited clinical efficacy or high recurrence
rates," said Jim Schutz, CEO of Oculus."We believe the rapidpatient
enrollment is indicative of the need for effective and safe management of
scars. We remain optimistic about achieving our intended results and upon FDA
clearance, anticipate that our U.S. dermatology partner, AmDerma/Quinnova,
will launch later in 2013."

AmDerma/Quinnova has agreed to pay Oculus a milestone payment at the time
ofthe FDA pre-market notification clearance that will reimburse Oculus for
the cost of this trial.

Scar Treatment Market

According to a 2003 report byFrost & Sullivan, it is estimated that 62
million scars are formed each year inthe United States. There are about 93
million people inthe United Statessuffering from scars, out of which about
169 million scars can be characterized as hypertrophic (raised) and keloid
(red colored) scars. The raised and red scars market forms the primary target
for the scar therapy products. Annually, about 600,000 visits for burns and
more than 2.6 million emergency room visits for cut injuries, this forms the
potential market for the scar therapy products. The statistics show that out
of 6.2 million reconstructive procedures performed on patients in a year,
250,000 surgeries are related with scar revisions.

About AmDerma Pharmaceuticals/Quinnova Pharmaceuticals

AmDerma Pharmaceuticals is a privately held company engaged in the development
of pharmaceutical products with dermatological indications.Quinnova
Pharmaceuticals, Inc., a wholly owned subsidiary of AmDerma Pharmaceuticals,
is a specialty pharmaceutical company founded on innovative, patent-protected
dermal delivery technologies.Our delivery platforms are utilized to transport
safe and effective pharmaceutical ingredients through the epidermis in unique,
convenient, and cosmetically elegant formulations.Addressing a wide variety
of skin conditions, it is our mission to provide superior treatment solutions
and product value to clinicians and patients alike.For more information,
please visit www.quinnova.com.

About Oculus Innovative Sciences

Oculus Innovative Sciences, Inc. is a commercial healthcare company that
designs, produces and markets innovative, safe and effective drugs, devices
and nutritional products. Oculus is pioneering innovative solutions in
multiple markets for the dermatology, surgical, wound care and animal
healthcare markets, and has commercialized products in the United States,
Europe, India, China, Mexico and select Middle East countries. The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found at
www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and future financial
performance. These forward-looking statements are identified by the use of
words such as "expects," "achieving," and "submit" among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, including such risks that regulatory clinical and guideline
developments may change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals, clinical results may not be replicated in actual patient settings,
protection offered by the Company's patents and patent applications may be
challenged, invalidated or circumvented by its competitors, the available
market for the Company's products will not be as large as expected, the
Company's products will not be able to penetrate one or more targeted markets,
revenues will not be sufficient to fund further development and clinical
studies, the Company may not meet its future capital needs, and its ability to
obtain additional funding, as well as uncertainties relative to varying
product formulations and a multitude of diverse regulatory and marketing
requirements in different countries and municipalities, and other risks
detailed from time to time in the Company's filings with the Securities and
Exchange Commission including the annual report on Form 10-K for the year
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:
        
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105
 
Press spacebar to pause and continue. Press esc to stop.